180 Life Sciences Corp (ATNF)
2.50
-0.18
(-6.72%)
USD |
NASDAQ |
Nov 15, 16:00
2.62
+0.12
(+4.80%)
After-Hours: 20:00
180 Life Sciences Research and Development Expense (TTM): 2.226M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.226M |
| March 31, 2024 | 2.525M |
| December 31, 2023 | 2.784M |
| September 30, 2023 | 3.407M |
| June 30, 2023 | 2.938M |
| March 31, 2023 | 2.521M |
| December 31, 2022 | 2.433M |
| September 30, 2022 | 3.818M |
| Date | Value |
|---|---|
| June 30, 2022 | 3.797M |
| March 31, 2022 | 4.288M |
| December 31, 2021 | 3.948M |
| September 30, 2021 | 2.836M |
| June 30, 2021 | 2.720M |
| March 31, 2021 | 2.156M |
| December 31, 2020 | 2.293M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.156M
Minimum
Mar 2021
4.288M
Maximum
Mar 2022
2.979M
Average
2.784M
Median
Dec 2023
Research and Development Expense (TTM) Benchmarks
| Seelos Therapeutics Inc | 20.43M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |